Finance

Lists
Outlook: 27.3% bullish·3.0% bearish
Go to analysis
GSK:NYSE
GSK plc
48,58 $
-1,34%
(-0,66) 1D
48,58 $
0,00% (0,00)
After hours
Closed: 18 նոյ, 16:00:02 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
49,03 $
High
49,49 $
Low
48,54 $
Mkt. cap
98,33 մլրդ
Avg. vol.
4,82 մլն
Volume
2,20 մլն
Dividend
3,78%
Quarterly dividend
0,46 $
Ex-dividend date
12 նոյ, 2026 թ.
P/E ratio
17,22
52-wk high
61,70 $
52-wk low
45,80 $
EPS
2,82 $
Beta
0,20
Shares outstanding
2,02 մլրդ
No. of employees
67 հզր
Open
49,03 $
High
49,49 $
Low
48,54 $
Mkt. cap
98,33 մլրդ
Avg. vol.
4,82 մլն
Volume
2,20 մլն
Dividend
3,78%
Quarterly dividend
0,46 $
Ex-dividend date
12 նոյ, 2026 թ.
P/E ratio
17,22
52-wk high
61,70 $
52-wk low
45,80 $
EPS
2,82 $
Beta
0,20
Shares outstanding
2,02 մլրդ
No. of employees
67 հզր
News stories
From web sources and news partners
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 հզր
Founded27 դեկ, 2000 թ.
Headquarters-
SectorHealth Care
Industry-
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current 48,58 $
60,00 $ (+23,51%)
Average
57,95 $ (+19,29%)
Lowest
55,90 $ (+15,07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Leuchten
Jefferies
Hold
Downgraded
55,90 $
+15,1%
10/28/2026
Unknown Analyst
Berenberg Bank
Buy
Upgraded
60,00 $
+23,5%
09/15/2026
Steve Scala
TD Cowen
Hold
Maintained
70,00 $
+44,1%
08/03/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/08/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
01/29/2026
Last report
28 հոկ, 2026 թ.
Fiscal period
Q3 2026
1,45 £ / 1,33 £
+9,46%beat
Revenue / Est. (GBP)
8,89 մլրդ / 8,84 մլրդ
+0,54%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
8,62 մլրդ
7,63 մլրդ
8,41 մլրդ
8,89 մլրդ
Cost of goods sold
2,62 մլրդ
1,87 մլրդ
2,07 մլրդ
2,24 մլրդ
Cost of revenue
2,62 մլրդ
1,87 մլրդ
2,07 մլրդ
2,24 մլրդ
Research and development expenses
2,14 մլրդ
1,52 մլրդ
1,75 մլրդ
1,90 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,67 մլրդ
2,08 մլրդ
2,19 մլրդ
2,17 մլրդ
Operating expense
4,37 մլրդ
2,99 մլրդ
3,74 մլրդ
4,06 մլրդ
Total operating expenses
6,99 մլրդ
4,86 մլրդ
5,81 մլրդ
6,30 մլրդ
Operating income
1,63 մլրդ
2,77 մլրդ
2,60 մլրդ
2,59 մլրդ
Other non operating income
-21,00 մլն
-
-
-
EBT including unusual items
950,00 մլն
2,14 մլրդ
354,00 մլն
1,94 մլրդ
EBT excluding unusual items
1,48 մլրդ
2,62 մլրդ
2,48 մլրդ
2,39 մլրդ
Income tax expense
223,00 մլն
305,00 մլն
-199,00 մլն
232,00 մլն
Effective tax rate
23,47%
14,23%
-56,21%
11,99%
Other operating expenses
-434,00 մլն
-615,00 մլն
-204,00 մլն
-17,00 մլն
Net income
636,00 մլն
1,74 մլրդ
435,00 մլն
1,54 մլրդ
Net profit margin
7,38%
22,77%
5,17%
17,36%
Earnings per share
-
-
-
-
Interest and investment income
17,00 մլն
22,00 մլն
58,00 մլն
29,00 մլն
Interest expense
-145,00 մլն
-167,00 մլն
-182,00 մլն
-219,00 մլն
Net interest expenses
-128,00 մլն
-145,00 մլն
-124,00 մլն
-190,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
2,69 մլրդ
3,23 մլրդ
2,82 մլրդ
3,33 մլրդ
Gain or loss from assets sale
-40,00 մլն
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps